EUCTR2019-003011-55-IT招募中1 期
Mesalamine for Colorectal Cancer Prevention Program in Lynch syndrome - MesaCAPP
Karolinska Institutet - Department of Medicine, Solna0 个研究点目标入组 260 人开始时间: 2021年6月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Proven tumor-free (including patients in which the polyps are removed endoscopically) carriers of a germline pathologic mutation on one of the MMR genes including MLH1, MSH2 (including EpCAM) and MSH6
- •Male or female subjects with the age > 30 years
- •Females who have been post-menopausal more than one (1) year or females of childbearing potential using a highly efficient method of contraception with less than 1% failure rate (i.e. oral hormonal contraceptives, hormone implants, hormone injections, sterilization, hormonal or copper intrauterine device, sterilized/vasectomized partner, or diaphragm in combination with a condom, spermicide or birth control pills) or should agree to abstain from heterosexual activity during treatment period.
- •Females of childbearing potential must have a negative pregnancy test at screening and randomization.
- •Signed written informed consent prior to inclusion in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 160
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Presence of colorectal endoscopically non-removable benign neoplasia (patient can be included if the adenoma is removed)
- •Carriers of germline mutations in PMS2
- •Patients with history of stage 3 and 4 colorectal cancer (CRC)
- •Presence of any metastatic disease
- •Regular use of acetylsalicylic acid (ASA or aspirin): daily use of =100mg in more than 3 continuous months within the last year
- •Regular use of NSAIDs or COX-2 inhibitors: daily use in more than 3 continuous months within the last year
- •Hypersensitivity to 5-ASA
- •Patients after any subtotal or total colectomy
- •Colorectal surgery within the previous 6 months
- •Unwillingness to participate or who is considered unable to give an informed consent
- •Pregnant or breastfeeding women
- •Participation in another clinical study investigating another IMP within 3 months prior to screening
- •Renal insufficiency (GFR <30ml/min/1.73m2)
- •Severe liver disease or liver failure (elevation of liver enzymes above 3xULN)
- •Current or history of serious psychiatric disorder or alcohol/drug abuse that in the opinion of the investigator may impact the assessment of IMP safety and efficacy or protocol adherence
- •Prior history of myocarditis or pericarditis. Other severe acute or chronic medical condition (such as severe chronic lung (COPD, including asthma), kidney or heart diseases), duodenal ulcer, haemorrhagic diathesis or psychiatric condition or other abnormal clinical sign or laboratory abnormality that may increase the risk associated with study participation or ability to comply with study procedures, IMP administration and, in the judgment of the investigator, would make the subject inappropriate for entry into this study
研究者
相似试验
进行中（未招募）
1 期
Mesalamine for Colorectal Cancer Prevention Program in Lynch syndromeColorectal Cancer Prevention in Lynch syndromeMedDRA version: 20.0 Level: LLT Classification code 10051981 Term: Lynch syndrome System Organ Class: 100000004850EUCTR2016-003548-35-ATMedical University of Vienna540
撤回
2 期
Mesalamine for Colorectal Cancer Prevention Program in Lynch syndromeNL-OMON44695Medical University of Vienna170
进行中（未招募）
1 期
Mesalamine administration to prevent development of colorectal cancer in Lynch syndrome.ynch Syndrome, which is increasing the risk of developing colorectal cancer.MedDRA version: 20.0Level: LLTClassification code 10051981Term: Lynch syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 21.0Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003011-55-DKKarolinska University Hospital360
进行中（未招募）
1 期
Mesalamine for Colorectal Cancer Prevention Program in Lynch syndromeColorectal Cancer Prevention in Lynch syndromeMedDRA version: 20.0 Level: LLT Classification code 10051981 Term: Lynch syndrome System Organ Class: 100000004850EUCTR2016-003548-35-SEMedical University of Vienna540
招募中
2 期
Mesalamine administration to prevent development of colorectal cancer in Lynch syndrome2024-514765-19-01Karolinska Institutet150